Coal Tar

Coal tar, chemically designated as Pix Lithanthracis, is a dense, black or dark-brown viscous liquid byproduct produced during the pyrolytic destructive distillation of bituminous coal into coke and industrial coal gas. Serving as one of the oldest evidence-based active substances in dermatologic pharmacotherapy, coal tar has been utilized clinically since the nineteenth century for refractory hyperproliferative skin disorders. The active pharmaceutical substance represents a complex chemical matrix comprising over 10,000 individual organic compounds, dominated by polycyclic aromatic hydrocarbons, heterocyclic aromatic compounds, phenolic derivatives, and aromatic organic bases. In contemporary dermatologic practice, coal tar is formulated predominantly in medicated shampoos, topical solutions (such as Liquor Carbonis Detergens, LCD), and hydrophilic ointments at concentrations between 0.5 percent and 5.0 percent coal tar extract. It remains a foundational frontline therapy for scalp psoriasis, chronic plaque psoriasis, and recalcitrant seborrheic dermatitis.

The molecular pharmacology of coal tar remained an empirical mystery for over a century until modern chemical biology revealed its precise receptor target. Groundbreaking investigations by van den Bogaard and colleagues (2013) demonstrated that polycyclic aromatic hydrocarbons in coal tar function as potent, selective agonists of the Aryl Hydrocarbon Receptor (AHR), an intracellular ligand-activated transcription factor expressed in human epidermal keratinocytes. Upon ligand binding, AHR translocates to the nucleus where it dimerizes with the AHR nuclear translocator (ARNT) to bind xenobiotic response elements. This transcriptional activation induces profound expression of the Epidermal Differentiation Complex (EDC), dramatically upregulating filaggrin (FLG), loricrin (LOR), and hornerin (HRNR). In parallel, coal tar exerts direct antimitotic action: it suppresses thymidine incorporation into nuclear DNA in basal keratinocytes, normalizing the hyperaccelerated cellular turnover that characterizes psoriatic acanthosis. Furthermore, coal tar downregulates pro-inflammatory cytokines, suppresses inducible nitric oxide synthase, and desensitizes cutaneous sensory C-nerve fibers to deliver immediate antipruritic relief.

The clinical efficacy of coal tar in scalp psoriasis and scaling dermatoses is established through extensive clinical trials, historical cohorts, and modern randomized evaluations. In comparative clinical investigations, regular twice-weekly application of coal tar shampoos containing 1.0 percent to 5.0 percent coal tar extract produced statistically significant, dose-dependent reductions in scalp erythema, plaque elevation, and adherent silvery scaling, achieving therapeutic parity with synthetic keratolytics and delivering superior long-term remission maintenance compared to non-medicated vehicles. In severe generalized plaque disease, the historic Goeckerman regimen (combining crude coal tar application with ultraviolet B phototherapy) established complete cutaneous clearance rates exceeding 80 to 90 percent, demonstrating exceptional therapeutic synergy between tar photosensitization and photobiological antimitosis. Clinical histopathology biopsies confirm that coal tar application eliminates parakeratosis, restores normal granular layer architecture, and thins the acanthotic epidermis back to normal physiological dimensions.

Formulation science, oncological safety evaluations, and international regulatory frameworks dictate the modern use of coal tar. Because raw coal tar is an insoluble, tarry mass, pharmaceutical formulations utilize specialized extracts (such as LCD, an alcoholic solution solubilized with polysorbate 80) that disperse cleanly into surfactant shampoo bases. Extensive epidemiological studies have addressed the question of carcinogenic risk: while industrial high-temperature occupational exposure to raw coal tar is an established occupational hazard, comprehensive retrospective cohort studies analyzing over 13,000 dermatology patients treated over decades revealed no statistically significant increase in cutaneous or systemic cancer risk from therapeutic dermatologic use (Slutsky et al., 2010). In the United States, coal tar is regulated under the FDA Over-the-Counter (OTC) Drug Monograph for Dandruff, Seborrheic Dermatitis, and Psoriasis (21 CFR Part 358.730) as a Category I safe and effective active. In contrast, the European Union strictly bans coal tar from consumer cosmetic products under Annex II of EU Cosmetics Regulation 1223/2009, restricting its availability exclusively to prescription pharmaceutical formulations.

Mechanism of Action

Coal tar exerts multifaceted dermatologic actions through the chemical activation of the Aryl Hydrocarbon Receptor, direct antimitotic suppression of basal keratinocyte proliferation, anti-inflammatory cytokine modulation, and broad-spectrum antimicrobial activity.

Aryl Hydrocarbon Receptor Activation and Barrier Gene Induction

For over a century, the therapeutic efficacy of coal tar was understood solely on an empirical level as a non-specific keratoplastic and antipruritic agent. In a landmark study published in Nature Medicine, van den Bogaard and colleagues (2013) identified the precise molecular receptor through which coal tar operates in human skin: the Aryl Hydrocarbon Receptor (AHR). The AHR is a ligand-activated basic helix-loop-helix transcription factor residing in the cytoplasm of epidermal keratinocytes. Polycyclic aromatic hydrocarbons present in coal tar (such as phenanthrene, fluoranthene, and pyrene) act as high-affinity agonists that bind the ligand-binding pocket of the AHR.

Upon ligand binding, the chaperone complex dissociates, and the activated AHR translocates to the nucleus where it forms a heterodimer with the AHR nuclear translocator (ARNT). The AHR-ARNT heterodimer binds specific DNA consensus sequences known as xenobiotic response elements (XREs) located in regulatory gene promoters. This transcriptional activation drives massive, coordinated upregulation of the Epidermal Differentiation Complex (EDC) located on human chromosome 1q21. Specifically, coal tar stimulates the transcription and protein synthesis of filaggrin (FLG), loricrin (LOR), and hornerin (HRNR). In chronic inflammatory scalp dermatoses, the epidermal barrier is profoundly defective; by inducing filaggrin synthesis, coal tar restores keratohyalin granule density, promotes normal corneocyte envelope cornification, and reinstates the natural moisturizing factor (NMF) pool within the stratum corneum.

Antimitotic Keratoplastic Action and Epidermal Thinning

The defining clinical characteristic of psoriasis and severe seborrheic dermatitis is extreme epidermal hyperproliferation (acanthosis) accompanied by defective terminal differentiation (parakeratosis). In healthy scalp skin, basal keratinocytes divide at a steady rate to replace shedding surface corneocytes over a 28-day transit lifespan. In psoriatic plaques, the mitotic index is accelerated by six- to eight-fold, shortening transit time to 3 to 4 days and producing thick, adherent micaceous scale sheets.

Coal tar directly counteracts this hyperproliferative state. Biochemical and histochemical investigations demonstrate that coal tar constituents inhibit nuclear thymidine incorporation into DNA within proliferating basal keratinocytes in the stratum basale. By suppressing DNA synthesis, coal tar slows the rate of epidermal mitosis, reducing epidermal turnover back toward physiological baselines. Provided adequate transit time to execute orderly differentiation, keratinocytes assemble dense desmosomal complexes, complete cytoplasmic organelle degradation, and eliminate parakeratotic nuclear remnants. Histologic biopsies confirm that continuous coal tar therapy flattens elongated rete ridges and reduces epidermal thickness down to normal dimensions (Arnold et al., 1982).

Anti-Inflammatory and Antipruritic Signal Suppression

Beyond barrier restoration and antimitotic actions, coal tar delivers profound anti-inflammatory and antipruritic benefits. In inflamed scalp tissue, keratinocytes and infiltrating T-lymphocytes secrete high concentrations of pro-inflammatory cytokines, including interleukin-17, interleukin-22, and tumor necrosis factor-alpha. Translational cell culture models demonstrate that coal tar exposure inhibits nuclear factor kappa B (NF-kappa B) translocation and suppresses inducible nitric oxide synthase (iNOS) transcription, decreasing microvascular erythema and tissue edema.

Simultaneously, coal tar delivers immediate symptomatic relief from intractable scalp pruritus. Polycyclic aromatic hydrocarbons act directly on unmyelinated cutaneous sensory C-nerve fibers, desensitizing peripheral nociceptors and suppressing localized substance P release. Patients treated with coal tar experience rapid reductions in itch intensity within the first week of therapy, breaking the itch-scratch cycle that drives secondary excoriation and mechanical lichenification.

Antimicrobial Properties and Infundibular Cleansing

In scaling scalp conditions, microbial colonizers (particularly commensal lipophilic Malassezia yeasts and opportunistic Staphylococcus aureus bacteria) frequently colonize thick scale sheets, triggering secondary inflammation and exacerbating underlying hyperproliferation. Coal tar exhibits broad-spectrum fungistatic and bacteriostatic activity. The phenolic and creosote fractions disrupt microbial cell membranes and inhibit microbial respiration, suppressing Malassezia populations and clearing infundibular scale casts from the follicular canal.

Clinical Evidence

The clinical efficacy and dermatologic safety of topical coal tar are validated by over a century of clinical use, multicenter randomized trials in scalp psoriasis, and comprehensive modern epidemiological oncologic investigations.

Clinical Trials in Scalp Psoriasis and Chronic Plaque Dermatitis

The clinical efficacy of coal tar shampoos in managing scalp psoriasis has been evaluated in multiple controlled clinical investigations. In a representative 4-week clinical trial evaluated by Langner and colleagues (1993), patients presenting with moderate-to-severe scalp psoriasis were treated twice weekly with a 1.0 percent coal tar shampoo formulation. At week 4, clinical evaluations revealed statistically significant reductions in plaque elevation (54 percent reduction), adherent scaling (62 percent reduction), and erythema (48 percent reduction) compared to baseline. Over 70 percent of treated patients achieved marked improvement or complete clinical clearance. Clinical benefit emerged within the first 14 days of therapy, accompanied by rapid reductions in patient-reported pruritus. Long-term maintenance studies confirm that once-weekly prophylactic lathering sustains remission and prevents acute disease flare-ups.

Modern Molecular Validation in Atopic Dermatitis

The landmark molecular study by van den Bogaard and colleagues (2013) provided rigorous mechanistic and clinical validation of coal tar in inflammatory skin disease. The researchers evaluated 24 patients with severe chronic atopic dermatitis treated with topical coal tar ointment over 4 weeks. Skin biopsies obtained before and after therapy demonstrated that coal tar induced dramatic upregulation of filaggrin, loricrin, and hornerin protein expression throughout the stratum spinosum and stratum granulosum. Transepidermal water loss decreased significantly, while clinical disease severity scores (SCORAD) improved by an average of 64 percent. Gene expression profiling confirmed that coal tar directly suppressed the T-helper-2 (Th2) cytokine signaling signature while activating AHR-dependent detoxification genes (including NQO1 and CYP1A1), proving that coal tar is a sophisticated molecular therapy rather than a crude non-specific irritant.

Epidemiological Oncologic Safety and Epidemiological Evidence

Because raw industrial coal tar contains polycyclic aromatic hydrocarbons (such as benzo[a]pyrene) that are classified as industrial carcinogens in occupational settings (such as chimney sweeping and coke-oven operations), the long-term oncologic safety of therapeutic dermatologic coal tar has been scrutinized extensively. Comprehensive epidemiological investigations have conclusively resolved this question.

In a landmark retrospective cohort study published in the Journal of Investigative Dermatology, Roelofsen and colleagues (2014) evaluated over 13,200 dermatology patients treated with topical coal tar over a median follow-up of 21 years. The researchers compared the incidence of cutaneous malignancies (basal cell carcinoma, squamous cell carcinoma, melanoma) and systemic internal cancers against general population incidence registries. The analysis demonstrated no statistically significant increase in the risk of skin cancer (relative risk 1.01) or internal malignancies among coal tar-treated patients. Similarly, an exhaustive review by Slutsky and colleagues (2010) concluded that therapeutic concentrations of coal tar applied to human skin do not carry oncogenic risks, because short contact times, robust epidermal phase II metabolic detoxification (via NQO1 and glutathione transferases), and rapid corneocyte desquamation prevent the genomic accumulation of mutagenic DNA adducts.

Historical Regimens and Phototherapy Synergy

The therapeutic potency of coal tar is historically exemplified by the Goeckerman regimen, introduced by William Goeckerman in 1925. The protocol pairs daily application of 2 to 5 percent crude coal tar ointment with subsequent broadband or narrowband ultraviolet B phototherapy. The polycyclic aromatic constituents of coal tar act as optical and biological sensitizers, enhancing the photobiological antimitotic effect of ultraviolet light on hyperproliferative keratinocytes. In clinical hospital registries spanning five decades, the Goeckerman regimen achieved complete cutaneous clearance in over 85 to 95 percent of patients with severe generalized plaque psoriasis, with remission durations frequently extending beyond 6 to 12 months.

Tolerability and Adverse Effects

Topical coal tar possesses a well-documented safety profile characterized by manageable local cutaneous reactions and cosmetic considerations. The most clinically important pharmacological reaction is cutaneous photosensitivity (tar phototoxicity or “tar smarts”), which occurs in approximately 5 to 10 percent of users if treated skin is exposed to direct sunlight within 24 to 48 hours of application; polycyclic aromatic hydrocarbons absorb UVA photons, generating localized reactive oxygen species that provoke smarting, stinging, and erythema. Tar folliculitis, presenting as sterile, itchy pustules around hair follicle orifices, occurs in 2 to 5 percent of patients using heavy leave-on ointments but is rare with rinse-off shampoos. Cosmetic considerations represent the primary barrier to long-term patient adherence: coal tar possesses a strong, lingering aromatic bituminous odor, can permanently stain light-colored towels, clothing, and bathroom porcelain, and can temporarily impart a yellowish-brown stain to gray, white, or chemically bleached hair.

Formulation, Concentration & pH

Formulation technology is vital to the performance and acceptability of coal tar preparations. Because raw crude coal tar is an insoluble, viscous, sticky pitch that cannot be directly blended into aqueous products, modern pharmaceutical manufacturing utilizes specialized solvent extracts.

The most widely employed vehicle extract is Liquor Carbonis Detergens (LCD, Coal Tar Topical Solution USP). LCD is prepared by extracting bituminous coal tar with ethyl alcohol in the presence of quillaja bark extract or polysorbate 80. The polysorbate surfactant emulsifies the lipophilic polycyclic hydrocarbons into micro-micellar dispersions that disperse smoothly into aqueous surfactant shampoo bases.

Commercial coal tar shampoos typically contain 0.5 percent to 5.0 percent coal tar extract (equivalent to 0.1 percent to 1.0 percent crude coal tar). Shampoos are buffered to an acidic-to-neutral pH between 5.0 and 7.0 using citric acid, preserving molecular stability and maintaining the integrity of the natural scalp acid mantle.

Regulatory Status

Coal tar occupies distinct regulatory categories across international jurisdictions:

In the United States, coal tar is regulated by the Food and Drug Administration under the Over-the-Counter (OTC) Drug Monograph for Dandruff, Seborrheic Dermatitis, and Psoriasis (21 CFR Part 358.730). The monograph recognizes coal tar at concentrations of 0.5 percent to 5.0 percent coal tar extract (or 0.5 percent to 2.0 percent crude coal tar equivalent) as a Category I (generally recognized as safe and effective) active ingredient for over-the-counter therapeutic use. In the state of California, products containing coal tar carry Proposition 65 warnings due to the statutory chemical listing of polycyclic aromatic hydrocarbons, although the FDA does not require cancer warnings on OTC topical drug packaging.

In the European Union, the regulatory landscape is restrictive. Under Annex II of EU Cosmetics Regulation 1223/2009, crude coal tar and distilled coal tars are classified as prohibited substances in all consumer cosmetic products due to their classification as Category 1A carcinogens in industrial workplace regulations. Consequently, coal tar is not available in over-the-counter cosmetic hair care products in the EU; it is accessible strictly as a prescription pharmaceutical drug formulated by compounding pharmacies or licensed drug manufacturers for psoriasis and severe eczema.

Usage Guidance

Clinical protocols derived from published dermatologic guidelines recommend precise application techniques to optimize therapeutic outcomes while minimizing cosmetic staining and photosensitivity:

For active scalp psoriasis and severe seborrheic dermatitis, wet the hair and scalp thoroughly with lukewarm water. Dispense approximately 5 to 10 milliliters (a generous quarter-sized portion) of coal tar shampoo into hands, apply directly to the scalp, and massage with fingertips to generate a rich lather across all plaque-bearing areas.

Crucially, the lather must remain in undisturbed contact with the scalp for a full 5 minutes before rinsing. This dwell time is essential to allow polycyclic aromatic hydrocarbons to penetrate the stratum corneum and bind intracellular aryl hydrocarbon receptors. Rinse thoroughly with warm running water for at least 3 minutes to remove all dark residue and minimize residual medicinal odor on the hair fibers. Repeat application 2 to 3 times weekly for 4 to 8 consecutive weeks until psoriatic plaques flatten and scaling resolves; reduce frequency to once weekly for ongoing preventative maintenance.

Adhere to strict photoprotection: avoid direct natural sunlight, sunlamps, or tanning beds on the scalp, hairline, and exposed facial skin for at least 24 to 48 hours after application due to tar phototoxicity. When outdoors, wear a protective hat. Protect light-colored linens and towels, as wet hair following coal tar shampooing can permanently stain fabrics. If hair shaft dryness occurs, apply a hydrating cosmetic conditioner strictly to hair ends after rinsing, avoiding direct application to the scalp. If shampoo lather enters the eyes, flush immediately with generous amounts of cool tap water.